IP Library Granted Patent US 7,838,564
Granted Patent B2
US 7,838,564 · App. 12/549,258 · Granted Nov 23, 2010

Stabilized compositions of volatile alkylating agents and methods of using thereof

Assignee: Yaupon Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,564
App. No.
12/549,258
Granted
Nov 23, 2010
Kind
B2
Abstract

A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.

Claims (9)

1. A composition comprising: (a) bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable excipient, wherein

the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.001% to about 2.0% by weight of the composition; and

the pharmaceutically acceptable excipient is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 1-6 carbon atoms.

2. The composition of claim 1 , wherein the bis-(2-chloroethyl)methylamine is in the form of an acid-addition or base-addition salt.

3. The composition of claim 2 , wherein the acid-addition salt is an HCl, HBr, H 1 , H 2 SO 4 , or HNO 3 salt.

4. The composition of claim 1 , wherein the pharmaceutically acceptable excipient is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 2 carbon atoms (ethoxy diglycol reagent).

5. The composition of claim 1 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01% to about 0.04% by weight of the composition.

6. The composition of claim 3 , wherein the acid-addition salt is an HCl salt.

7. The composition of claim 6 , wherein the pharmaceutically acceptable excipient is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 2 carbon atoms (ethoxy diglycol reagent).

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2020
From: ACTELION PHARMACEUTICALS LTD
To: HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 051542/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: CEPTARIS THERAPEUTICS, INC.
To: ACTELION PHARMACEUTICALS, LTD.
Reel/Frame 031896/0320 →
CHANGE OF NAME Recorded Feb 24, 2012
From: YAUPON THERAPEUTICS, INC.
To: CEPTARIS THERAPEUTICS, INC.
Reel/Frame 027757/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2011
From: ALONSO, ROBERT; CROOKS, PETER A.; PIMLEY, MARK A.
To: YAUPON THERAPEUTICS, INC.
Reel/Frame 027299/0903 →
Continuity (4)
Division 1136930500 · Mar 7, 2006
Provisional Application 6075112800 · Dec 16, 2005
Provisional Application 6066135600 · Mar 14, 2005
Related Publication 20100041767A1 · Feb 18, 2010